Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
The Journal of Clinical Endocrinology & Metabolism · 21.01.2025 · 110 (Supplement_1) · S25-S36
DOI: 10.1210/clinem/dgae718 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.01.2025. Verfasst von Hedi L Claahsen-van der Grinten und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Endocrinology, Amalia Children's Hospital, Radboud University Medical Center, 6500 HB Nijmegen, the N…. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Glucocorticoids. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency results in severe cortisol and aldosterone deficiency, leading to persistent adrenal stimulation and excess production of ACTH and adrenal androgens. This review examines the clinical considerations and challenges of balancing under- and overtreatment with glucocorticoids in adolescent and adult male individuals with CAH. Adolescents face many unique challenges that can hinder adherence, hormonal control, and transition to independence. Thus, patient education is critical during adolescence, especially in poorly controlled postpubertal males who lack obvious symptoms and may not recognize the long-term consequences of nonadherence, such as reduced final height, reduced reproductive health, poor bone health, obesity, and hypertension. The risk of subfertility/infertility begins early, especially in males with poor hormonal control, who often have reduced sperm counts, small testes, and benign tumors called testicular adrenal rest tumors (TARTs). Even males with good hormonal control can experience subfertility/infertility due to TARTs. In addition, several factors such as hypogonadism and long-term glucocorticoid treatment can predispose males with CAH to poor bone health (eg, low bone mineral density, increased risk of osteoporosis/osteopenia and fractures) and metabolic syndrome (eg, obesity, insulin resistance, dyslipidemia, and hypertension). Regular monitoring is recommended, with glucocorticoid dose optimization and prophylactic treatment to maximize future fertility potential and protect long-term bone health. Early implementation of lifestyle interventions and medical treatment are needed to address cardiometabolic consequences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Endocrinology, Amalia Children's Hospital, Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.
- Department of Endocrinology, Karolinska University Hospital, 171 76 Stockholm, Sweden.
ORCID-Profile: Hedi L Claahsen-van der Grinten, Bas P H Adriaansen, Henrik Falhammar
Zitieren
APA
Claahsen-van der Grinten, H. L., Adriaansen, B. P. H., & Falhammar, H. (2025). Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism, 110(Supplement_1), S25-S36. https://doi.org/10.1210/clinem/dgae718
Vancouver
Claahsen-van der Grinten HL, Adriaansen BPH, Falhammar H. Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2025;110(Supplement_1):S25-S36. doi:10.1210/clinem/dgae718
BibTeX
@article{ClaahsenvanderGrinten2025,
author = {Claahsen-van der Grinten, Hedi L and Adriaansen, Bas P H and Falhammar, Henrik},
title = {Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {Supplement_1},
pages = {S25--S36},
doi = {10.1210/clinem/dgae718}
}
EUVIMED